Abstract
conditions including chronic alcoholism (1, 32) , inflammatory bowel disease (6, 18), inborn 55 errors of RF metabolism (2, 9, 11, 14) , and diabetes mellitus (16). In addition, it has been 56 suggested that low maternal RF level may increase the risk for development of fetal anomalies 57 including transverse and longitudinal limb deficiency, as well as congenital heart defects (29, 31, 58 39). In contrast to the negative effects of RF deficiency, optimizing RF body homeostasis is 59 effective in the treatment of patients with Fazio Londe syndrome, Brown-Vialetto Van Laere 60 syndrome (BVVLS) (2, 9, 11, 14) , and those with RF-responsive multiple acyl-CoA 61 dehydrogenase deficiency (20, 56) .
62
Humans and other mammals have lost the capability for de novo synthesis of RF and 63 therefore must acquire this micronutrient from exogenous sources via intestinal absorption. Two 64 sources of RF are available to the intestine: a dietary source (which is absorbed in the small 65 intestine) and a microbiota source (which is absorbed in the large intestine) (12, 15, 34, 40) .
66
Absorption of both sources of RF occurs via an efficient and specific carrier-mediated process hRFVT-2 appears to be mostly intracellular (with some at the BLM domain) (41, 45 ). An 75 essential role for RFVT-3 in intestinal RF uptake has also been established in studies by our 76 group utilizing in vitro gene-specific silencing approach (siRNA) and an intestinal-specific 77 conditional RFVT-3 (SLC53A3) knock out mouse model (45, 46) .
78
The human RFVT-3 is a 469 amino acid protein, and is predicted to have 11 79 transmembrane domains (TMDs) with the NH 2 -terminal tail being oriented toward the cell 
85
Further studies, however, are needed to delineate the structure-function activity of this important 86 vitamin transporter. Thus, our aim in this study was to address this issue with a specific focus 87 on determining the glycosylation status of the hRFVT-3 protein, and on identifiying residues that 88 are imporatnt for the function and cell biology of the membrane transporter. Our results showed 89 that the hRFVT-3 protein is glycosylated and that glycosylation is important for its function. Also a number of residues (those located at positions 16, 20, 24, 142, 314 and 315) were synthesized using Sigma Genosys (Woodlands, TX). The molecular biology grade 100 chemicals and reagents used in these studies were obtained from commercial sources.
101
Site-directed mutagenesis -For site-directed mutagenesis studies, the full-length 102 hRFVT-3 cloned into GFP-C3 vector (Clontech, CA) was used as a template. The Quick
103
Change II site-directed mutagenesis kit from Stratagen (La Jolla, CA) was used for mutating N-104 glycosylation and potentially interacting with RF residues and utilizing specifically designed 105 primers for each mutation ( HuTu-80 cells were selected using G418 (0.5 mg/ml) (Invitrogen) for 6-8 weeks as described 120 before (41). were estimated using a Bio-Rad protein assay kit.
126
Tunicamycin and PNGase F treatment -GFP-hRFVT-3 stably expressing HuTu-80 127 cells were treated with 2µg/ml tunicamycin for 24h and then these cells were used for western HeNe ion laser. Emitted fluorescence was monitored at 515 ± 30nm short pass and 570 ± 50nm 146 long pass filters, respectively. Images were captured and processed using Nikon C-1 software 147 and photoshop.
148
Comparative protein structure modeling -To obtain homology models, we subjected 149 the hRFVT-3 protein sequence to "Phyre2" fold recognition program
150
(http://www.sbg.bio.ic.ac.uk/phyre2) (17). We then validated the models using "ProSA-Web"
151
(https://prosa.services.came.sbg.ac.at/prosa.php) (50). The model we selected was the one that 152 uses the structure of the glucose transporter of Staphylococcus epidermidis (PDB ID: c4LDSB)
153
as the most suitable template (5), as it gave a 93% confidence. The generated three dimensional 154 (3D) structure of hRFVT-3 was visualized by "RasMol" (www.rasmol.org). This generated 155 model was then subjected to "DockingServer" (http://www.dockingserver.com) (10) to identify 156 the putative interacting residues with RF. The hRFVT-3 protein is glycosylated and glycosylation is important for its function -
166
The hydrophobicity analysis of the hRFVT-3 protein (469 amino acids) predicts the polypeptide 167 as having 11 transmembrane domains (TMDs), with the intracellular NH 2 -being oriented toward 168 cell interior while the COOH-terminal tail being oriented toward cell exterior (41, 51) ( Fig. 1) .
169
This analysis also predicts the hRFVT-3 protein as having two putative N-glycosylation sites stability (8, 19, 22, 25, 26, 44, 47, 49, 55) , we aimed in this study to determine whether the H-RF uptake compared to untreated control cells (Fig. 2B) .
189
In other studies, we performed live-cell confocal imaging of HuTu-80 cells expressing hRFVT-3 and treated with tunicamycin and observed numerous GFP-hRFVT-3 containing 191 intracellular vesicles in the tunicamycin treated compared to the untreated cells (Fig. 2C) . The
192
latter suggest that N-glycosylation is important for membrane targeting of the hRFVT-3 protein.
193
Taken together, these results suggest that the hRFVT-3 polypeptide is glycosylated and this
194
glycosylation is important for its function. hRFVT-3 mutants showed a significantly (P < 0.01 for both) lower induction in RF uptake 204 compared to those expressing the WT hRFVT-3 (Fig. 3) .
205
To determine whether the decrease in RF uptake by cells expressing the Asn (Fig.4) . The intracellular retention of the mutated hRFVT3 proteins 215 appeared to be in the endoplasmic reticulum (ER) as shown by co-localization studies with the 216 ER marker (DsRed-ER) (Fig.4) which is conserved only in human, rat and mouse RFVT-3 (Fig. 6B) . The schematic 239 representation of the hRFVT-3 secondary structure showing the predicted site of potential 240 interacting mutations locations in its 11 TMDs is shown in Figure 1 .
241

Effect of mutating the predicted potential interacting residues on hRFVT-3 function -
242
In these investigations, we mutated amino acids Ser by the significant overlap with the ER marker DsRed-ER) (Fig. 9) . In contrast, mutants GFP- to be expressed at the cell surface, but showed impaired function. This raises the possibility that 275 mutation at the 142 site of the hRFVT-3 leads to conformational change in the transport protein 276 which affects its interaction with its substrate; however, this suggestion remains to be confirmed.
277
Discussion
278
The hRFVT-3 is a physiologically and clinically relevant transporter as it is responsible 279 for intestinal uptake of an essential micronutrient, RF, and its mutation leads to significant those of other water-soluble vitamin transporters (8, 19, 22, 25, 26, 44, 47, 49, 55) . Moreover, 
309
In examining the amino acid residues in the hRFVT-3 protein that are predicted by the Western blot analysis after tunicamycin treatment of GFP-hRFVT-3 expressing HuTu-80 cells.
515
Western blotting was performed as described in "Methods". The images are representative of 
